Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process
Gothenburg, January 18, 2021 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that Vinnova has granted the company and its project partners 5 million SEK in grants to develop an automated process for CAR T-cell manufacturing.Elicera Therapeutics and its collaborators at Karolinska Institute and their production unit, Vecura at Karolinska Sjukhuset, Uppsala University and Akademiska Sjukhuset in Uppsala are preparing for